Melvin Chan MD

Current NSMC Faculty, CU Ped Neph, and IM faculty; interested in CKM and transition of care

[Brian Rifkin, MD @brian_rifkin]

🚨Check out another @KIReports community blog by @DrYellampalli on ADPKD

https://t.co/KDFkq6feqD

[Melvin Chan MD @MChanMD]

Great review on stopping the progression of ADPKD! Check it out!

[KIReports @KIReports]

1/ Hey #NephTwitter! Welcome to a #tweetorial #xtorial brought to you by
@KIReports

[KIReports @KIReports]

1/ Hey #NephTwitter! Welcome to a #tweetorial #xtorial brought to you by
@KIReports

[Melvin Chan MD @MChanMD]

The future direction of nephrology

[KIReports @KIReports]

2/🚨 Our topic🚨: A Comprehensive Framework for Kidney Function Assessment: Summary of the NIDDKD Reimagining Kidney Function Assessment Workshop.
There are no conflicts of interest. #MedSky #NephSky #MedTwitter #nephtwitter @ISNkidneycare
Article 👉https://t.co/zoAlV8jV7t. .

[Pediatric Nephrology @Ped_Neph]

CKD causes significant morbidity & mortality among children w/heart failure. Read this Original Article on heart-kidney transplant outcomes compared to heart-only transplants in children w/non-dialysis-dependent advanced CKD.
https://t.co/qoDY5yEj4U

[Melvin Chan MD @MChanMD]

Thrilled to have our review article on complement-mediated biomarkers published #NephTwitter #NephX. @DanaRizk1 @DrBradleyDixon @sydney_tang

https://t.co/hlmZd7aiof

[Melvin Chan MD @MChanMD]

More evidence showing that GLP1s may be modulate rheumatic disease #MedTwitter #NephTwitter:
https://t.co/btzDe2BLdB

and

https://t.co/6SvM7Xfx5X

[Melvin Chan MD @MChanMD]

More tools for advanced CKD!

[KIReports @KIReports]

🧵 New #Tweetorial Drop! 🧵
1/ Hey #NephTwitter! 👋
We’re back with a fresh #XTorial from @KIReports, this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭

[Melvin Chan MD @MChanMD]

@edgarvlermamd Are most adult nephrologist using sparsentan over Tarpeyo given greater proteinuria reduction? #NephPearls

[Melvin Chan MD @MChanMD]

Thoughts about Wegovy vs Zepbound for MACE Reduction? #MedTwitter #NephTwitter

Finding:
-Semaglutide showed 29% reduction

Limits:
-Small # of MACE
-Retrospective

Implications:
-Wegovy may be better for those with ASCVD
-Does GIP have any CV benefits?

https://t.co/LLZ5cKUk1K

[KIReports @KIReports]

Hey #NephTwitter! Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports @ISNkidneycare #XTwitter Our author is @elbaonelida nephrologist at Hospital General de Mexico @hgm_nefrologia. Please also check out https://t.co/m2eRz3qllA educational #blogposts. FOLLOW US!

[Melvin Chan MD @MChanMD]

For all my little beans out there, make sure to read the newest guidelines on IgAVN and IgAN by @md_abdulqader83 at @KIReports

https://t.co/veBh22wtLw

[Melvin Chan MD @MChanMD]

@KIReports @jmteakell Great work @DrBradleyDixon! Excited to see more of your work to come!!

[IPNA Ped Nephrology @IPNA_PedNeph]

❗Don't miss out!

This month: IPNA Journal Club📖 - IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis

🌟👉Free registration: https://t.co/qXDOUb6kHf

See you on Jan 16!

#pedneph #learning

[Brian Rifkin, MD @brian_rifkin]

Another @KIReports community blog. This time from me! This one is rather personal, as a physician with T1D (30 years in May 2025), I’ve fell a bit left out of all of the advances in diabetic nephropathy. Read more #NephTwitter #MedTwitter

https://t.co/tWoc7zziiL

[KIReports @KIReports]

1/23
Hey #NephTwitter!
Welcome to a 🆕 #tweetorial #xtorial #skeetorial (adding to the good place too) brought to you by @KIReports.
Want more, check out the blog here:
https://t.co/MXQZU3fusF

[Elba Medina @elbaonelida]

💥 Finally recognizing the connection between the heart, kidney & metabolic syndrome ‼️

Happy to share our blog @KIReports @sophia_kidney @brian_rifkin @MChanMD @ghobby @CTeodosiu @NephroSeeker @NSMCInternship @ISNkidneycare
👇🏻
https://t.co/Pny7DHNkfD

[Melvin Chan MD @MChanMD]

@captainchloride Thanks for sharing! I have been following you a lot peripherally. Curious if you mind sharing the study? Want to see who was in the study that came with this equation as I see some adolescents with Fontans and fluid overload

[Melvin Chan MD @MChanMD]

These Xtorials can all now be accessed via: https://t.co/uXLGgfrA1e

[Melvin Chan MD @MChanMD]

So proud of @stephanietr612 and @elbaonelida. They have grown up so much and soon will be graduating!! @NSMCInternship

[Stephanie Torres M.D. @stephanietr612]

Do you want to learn more about Nefecon’s adverse effects?
⬇️ Check out this Xtorial!
Thanks to @MChanMD @sophia_kidney @ghobby for your mentorship!

[Melvin Chan MD @MChanMD]

https://t.co/zDOMHcMQyA

[KIReports @KIReports]

1a/ What if there was a biomarker that could guide therapeutic decision-making in patients with IgA Nephropathy (IgAN)? 🤔